Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody

F. L. Day, J. Desai, Christopher Corless, Michael Heinrich, J. Zalcberg

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors lacking mutations in KIT or PDGFRα are known as wild type (WT) and are less responsive to imatinib. These WT tumors are hypothesized to be dependent on signaling through the insulin-like growth factor 1 receptor (IGF-1R). We report the case of a 29-year-old woman with neurofibromatosis type 1-associated WT GIST treated with an anti-IGF-1R monoclonal antibody. Treatment was ineffective, and the potential basis for lack of response is discussed in the context of IGF-1R expression levels measured within this patients' primary tumor. We suggest that future clinical trials of anti-IGF-1R therapies prospectively determine tumor IGF-1R expression levels for correlation with response to treatment.

Original languageEnglish (US)
JournalMedical Oncology
Volume28
Issue numberSUPPL. 1
DOIs
StatePublished - Dec 2011

Fingerprint

Somatomedin Receptors
Gastrointestinal Stromal Tumors
Neurofibromatosis 1
Monoclonal Antibodies
Neoplasms
Therapeutics
Clinical Trials
Mutation

Keywords

  • Gastrointestinal stromal tumor
  • Insulin-like growth factor
  • Insulin-like growth factor receptor type 1
  • Neurofibromatosis
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody. / Day, F. L.; Desai, J.; Corless, Christopher; Heinrich, Michael; Zalcberg, J.

In: Medical Oncology, Vol. 28, No. SUPPL. 1, 12.2011.

Research output: Contribution to journalArticle

@article{f9fed73c045c43c49fa1e5a96487cbac,
title = "Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody",
abstract = "Gastrointestinal stromal tumors lacking mutations in KIT or PDGFRα are known as wild type (WT) and are less responsive to imatinib. These WT tumors are hypothesized to be dependent on signaling through the insulin-like growth factor 1 receptor (IGF-1R). We report the case of a 29-year-old woman with neurofibromatosis type 1-associated WT GIST treated with an anti-IGF-1R monoclonal antibody. Treatment was ineffective, and the potential basis for lack of response is discussed in the context of IGF-1R expression levels measured within this patients' primary tumor. We suggest that future clinical trials of anti-IGF-1R therapies prospectively determine tumor IGF-1R expression levels for correlation with response to treatment.",
keywords = "Gastrointestinal stromal tumor, Insulin-like growth factor, Insulin-like growth factor receptor type 1, Neurofibromatosis, Targeted therapy",
author = "Day, {F. L.} and J. Desai and Christopher Corless and Michael Heinrich and J. Zalcberg",
year = "2011",
month = "12",
doi = "10.1007/s12032-010-9665-2",
language = "English (US)",
volume = "28",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody

AU - Day, F. L.

AU - Desai, J.

AU - Corless, Christopher

AU - Heinrich, Michael

AU - Zalcberg, J.

PY - 2011/12

Y1 - 2011/12

N2 - Gastrointestinal stromal tumors lacking mutations in KIT or PDGFRα are known as wild type (WT) and are less responsive to imatinib. These WT tumors are hypothesized to be dependent on signaling through the insulin-like growth factor 1 receptor (IGF-1R). We report the case of a 29-year-old woman with neurofibromatosis type 1-associated WT GIST treated with an anti-IGF-1R monoclonal antibody. Treatment was ineffective, and the potential basis for lack of response is discussed in the context of IGF-1R expression levels measured within this patients' primary tumor. We suggest that future clinical trials of anti-IGF-1R therapies prospectively determine tumor IGF-1R expression levels for correlation with response to treatment.

AB - Gastrointestinal stromal tumors lacking mutations in KIT or PDGFRα are known as wild type (WT) and are less responsive to imatinib. These WT tumors are hypothesized to be dependent on signaling through the insulin-like growth factor 1 receptor (IGF-1R). We report the case of a 29-year-old woman with neurofibromatosis type 1-associated WT GIST treated with an anti-IGF-1R monoclonal antibody. Treatment was ineffective, and the potential basis for lack of response is discussed in the context of IGF-1R expression levels measured within this patients' primary tumor. We suggest that future clinical trials of anti-IGF-1R therapies prospectively determine tumor IGF-1R expression levels for correlation with response to treatment.

KW - Gastrointestinal stromal tumor

KW - Insulin-like growth factor

KW - Insulin-like growth factor receptor type 1

KW - Neurofibromatosis

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84655176763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84655176763&partnerID=8YFLogxK

U2 - 10.1007/s12032-010-9665-2

DO - 10.1007/s12032-010-9665-2

M3 - Article

C2 - 20799000

AN - SCOPUS:84655176763

VL - 28

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - SUPPL. 1

ER -